Stereotaxis Inc(STXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.24 | Insider Own | 23.21% | Shs Outstand | 97.9M | Perf Week | -1.35% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 27.42% | Insider Trans | - | Shs Float | 76.9M | Perf Month | -16.77% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.05 | Inst Own | 42.98% | Short Float | 7.79% | Perf Quarter | -29.62% |
| Income | -0.02B | P/S | 3.19 | EPS this Y | 17.33% | Inst Trans | -2.34% | Short Ratio | 9.97 | Perf Half Y | -50.15% |
| Sales | 0.03B | P/B | 7.66 | EPS next 5Y | - | ROA | -46.14% | Short Interest | 5.99M | Perf YTD | -58.38% |
| Book/sh | 0.13 | P/C | 9.14 | EPS past 3/5Y | 0.82% -17.98% | ROE | -184.27% | 52W High | -66.88% ($2.89) | Perf Year | -64.55% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | 4.78% 3.99% | ROIC | -101.65% | 52W Low | 19.65% ($0.80) | Perf 3Y | -42.68% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.55% | Gross Margin | 55.57% | Volatility(W/M) | 12.69% 7.14% | Perf 5Y | -84.46% |
| Dividend TTM | - | EV/Sales | 3.19 | Sales Y/Y TTM | -5.47% | Oper. Margin | -65.23% | ATR (14) | 0.08 | Perf 10Y | 52.91% |
| Dividend Ex-Date | - | Quick Ratio | 0.94 | EPS Q/Q | -1.49% | Profit Margin | -78.45% | RSI (14) | 40.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.41 | Sales Q/Q | -12.82% | SMA20 | -4.25% ($1) | Beta | 1.4 | Target Price | $3 |
| Payout | - | Debt/Eq | 0.3 | Earnings | 2026/11/10 | SMA50 | -19.41% ($1.19) | Rel Volume | 2.13 | Prev Close | $0.84 |
| Employees | 131 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | - -8.14% | SMA200 | -43.1% ($1.69) | Avg Volume(3M) | 0.60M | Price | $0.96 |
| IPO | 2004/8/12 | Option/Short | Yes/Yes | Trades | 1846 | Volume | 1,282,694 | Change | 13.55% |
Stereotaxis is a US medical device company that develops robotic navigation systems specialized for cardiac electrophysiology procedures. The company is expanding its presence in the arrhythmia treatment market through its magnetic field-based remote catheter manipulation platform and digital operating room solutions. It carries both the growth potential and the volatility typical of micro-cap stocks.
Over the past 1 year, on the lower side
67% below its 1-year high.
Traded more than usual. That is 213% of its average volume.
Next earnings report: November 10
5 days to go.
STXS has weak earning power
Of every $100 in sales, $65.23 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $319. Peers typically go for $255.
Tap to view numbers
Results came in about as expected
Slight tendency to miss estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.5%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 43.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #38 of 51 in the industry
Based on market cap of $96M.
PDEX#36 Pro-Dex Inc $203M PER 17.4 
KRMD#37 KORU Medical Systems Inc $151M PER - STXS#38 Stereotaxis Inc $96M PER - 
POCI#39 Precision Optics Corp Inc $53M PER - 
DXR#40 Daxor Corp $52M PER 7.3 
FAQ
What kind of company is STXS?
STXS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of STXS?
The market cap of STXS is approximately $96M, ranking 4,483 within its sector.
What is the 52-week high and low for STXS?
STXS has recorded a 52-week high of $2.89 and a low of $0.80.
